Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC.

Xiao LiangWei ZhangJun LiJing ZhuJun ShaoJing WangHongshuai WuJiali DaiJun LiJiali XuWei WangRen-Hua Guo

Published in: Journal of cancer research and clinical oncology (2022)

Co-detection of EGFR mutation in tumor tissue and plasma is an independent prognostic factor for first-line EGFR-TKIs treatment. Moreover, combination therapy could be a promising approach to improve the outcome for these patients.

Keyphrases

small cell lung cancer
prognostic factors
combination therapy
epidermal growth factor receptor
tyrosine kinase
end stage renal disease
newly diagnosed
ejection fraction
patient reported outcomes
patient reported